Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM)
and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ …

The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although
surgery and radiation therapy have a role in the treatment of metastatic disease, systemic …

Purpose: Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) is
a promising treatment for metastatic melanoma unresponsive to conventional therapies. We …

The development of a drug-resistant cell line can take from 3 to 18 months. However, little is
published on the methodology of this development process. This article will discuss key …

Introduction Melanoma is the most serious form of skin cancer causing most of the skin
cancer-related deaths. The incidence of melanoma has risen so dramatically over past few …

Drug combination represents one of the most accredited strategies of cancer therapy able to
improve drug efficacy and possibly overcome drug resistance. Among the agents used to …

Melanoma is a relentless type of skin cancer which involves myriad signaling pathways
which regulate many cellular processes. This makes melanoma difficult to treat, especially …

Background The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor. Pre‐
clinical, adult phase I and II trials have demonstrated the combination of irinotecan and …

Abstract Purpose of Review In the preceding decade, the management of metastatic
cutaneous melanoma has been revolutionised with the development of highly effective …

Dendritic cells (DC) are the most potent antigen presenting cells and have proven effective
in stimulation of specific immune responses in vivo. Competing immune inhibition could limit …